Institute of Nanoengineering and Microsystems, National Tsing Hua University, Hsinchu 300, Taiwan.
Lab Chip. 2015 Jun 7;15(11):2357-63. doi: 10.1039/c4lc01052c. Epub 2015 Apr 29.
The purpose of this article is to demonstrate the capacity of paper-based ELISA (P-ELISA) to monitor VEGF in patients requiring treatment for vision-threatening diseases. The most commonly encountered vision-threatening diseases are age-related macular degeneration (AMD) and diabetic retinopathy (DR), both of which may require short-term or life-long anti-VEGF injection treatment therapy. Accurate measurement of VEGF concentration in aqueous humor can provide significant and timely information to diagnose the disease state. Adequate and precise therapy may consequently be provided. At odds with conventional diagnostic approaches is the fact that a maximum of only 200 microliters of aqueous humor can be safely removed from the eye for testing. Fortunately, new diagnostic platforms, such as P-ELISA, require only minute volumes, i.e., approximately 2 microliters per test "well" and approximately 40 microliters total to quantify VEGF levels, and the testing process takes less than an hour. Thus, point-of-care (POC) diagnostics, such as P-ELISA, should be examined and improved upon as needed in order to develop an efficient tool for outpatient clinics and others to obtain semi-quantitative results that might facilitate accurate dosing of anti-VEGF treatment and delay or prevent the progression of AMD and DR.
本文旨在展示基于纸张的 ELISA（P-ELISA）在监测需要治疗威胁视力疾病的患者的 VEGF 方面的能力。最常见的威胁视力的疾病是年龄相关性黄斑变性（AMD）和糖尿病性视网膜病变（DR），两者都可能需要短期或终身的抗 VEGF 注射治疗。准确测量房水中的 VEGF 浓度可以提供重要且及时的信息来诊断疾病状态。因此，可以提供足够和精确的治疗。与传统诊断方法不同的是，实际上最多只能从眼睛中安全地取出 200 微升的房水进行测试。幸运的是，新的诊断平台，如 P-ELISA，仅需要微量体积，即每个测试“孔”约 2 微升，总共约 40 微升即可定量 VEGF 水平，并且测试过程不到一个小时。因此，需要检查和改进即时护理（POC）诊断，如 P-ELISA，以开发一种用于门诊和其他机构的有效工具，以便获得半定量结果，从而有助于准确确定抗 VEGF 治疗的剂量并延迟或预防 AMD 和 DR 的进展。
